Latest & greatest articles for duloxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on duloxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on duloxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for duloxetine

41. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review

Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

42. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Girardi P, Pompili M, Innamorati M, Mancini M, Serafini G, Mazzarini L, Del Casale A, Tatarelli R, Baldessarini RJ CRD (...) summary The review found that duloxetine appeared more effective than placebo for acute major depression in adults, and was comparable to selective serotonin-reuptake inhibitors, but that more research is needed. In view of poor reporting of review methods and adverse event outcomes, and lack of statistical evidence that the trials were suitable for pooling, the authors’ conclusions may not be reliable. Authors' objectives To evaluate the efficacy and tolerability of duloxetine for acute major

2009 DARE.

43. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

44. Duloxetine hydrochloride - Major Depressive Disorder (MDD)

Duloxetine hydrochloride - Major Depressive Disorder (MDD) Common Drug Review CEDAC Meeting – July 16, 2008 Page 1 of 2 Notice of CEDAC Final Recommendation – August 14, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION DULOXETINE (Cymbalta ™ – Eli Lilly Canada Inc.) Description: Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the symptomatic relief of major depressive disorder in adults. Duloxetine is also approved (...) for the management of neuropathic pain associated with diabetic peripheral neuropathy. This submission to the Common Drug Review (CDR) deals only with its use in major depressive disorder. Dosage Forms: 30 mg and 60 mg delayed-release capsules. The recommended dose for depression is 60 mg daily. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that duloxetine not be listed for the treatment of major depressive disorder. Reasons for the Recommendation: 1. There is insufficient

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

45. Duloxetine hydrochloride - Neuropathic pain, Diabetic

Duloxetine hydrochloride - Neuropathic pain, Diabetic Common Drug Review CEDAC Meeting – July 16, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – August 14, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION DULOXETINE (Cymbalta ™ – Eli Lilly Canada Inc.) Description: Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the management of diabetic peripheral neuropathic pain. Duloxetine is also approved for the symptomatic relief (...) of major depressive disorder. This submission to the Common Drug Review relates solely to its use in diabetic peripheral neuropathic pain. Dosage Forms: 30 mg and 60 mg delayed-release capsules. The recommended dose is 60 mg daily. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that duloxetine be listed for the treatment of neuropathic pain in diabetic patients who are unresponsive to two adequate courses of less costly alternative agents such as a tricyclic

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

46. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial (PubMed)

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial The primary objectives of this study were to assess the efficacy and safety of duloxetine for reducing pain severity in fibromyalgia patients with or without current major depressive disorder. This was a 6-month, multicenter, randomized, double-blind, placebo-controlled study. In total, 520 (...) patients meeting American College of Rheumatology criteria for fibromyalgia were randomly assigned to duloxetine (20 mg/day, 60 mg/day, or 120 mg/day) or placebo, administered once daily, for 6 months (after 3 months, the duloxetine 20-mg/day group titrated to 60 mg/day). The co-primary outcome measures were the Brief Pain Inventory (BPI) average pain severity score and Patient Global Impressions of Improvement (PGI-I) score. Safety was assessed via treatment-emergent adverse events, and changes

2008 EvidenceUpdates

47. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Wade A G, Fernandez J L, Francois C, Hansen K, Danchenko N, Despiegel N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of escitalopram and duloxetine in the treatment of major depressive disorder (MDD) in the UK. The authors concluded that, from a UK societal perspective, escitalopram led to a reduction in costs and improved clinical outcomes in comparison

2008 NHS Economic Evaluation Database.

48. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Beard S M, McCrink L, Le T K, Garcia-Cebrian A, Monz B, Malik R A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the six-month costs and health benefits of using duloxetine as an additional treatment to the recommended current practice, in the UK, in diabetic patients experiencing peripheral neuropathic pain. The authors concluded that second-line duloxetine created potential cost-savings to the health system

2008 NHS Economic Evaluation Database.

49. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder

A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder Armstrong EP, Malone DC, Erder MH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of two branded treatments for major depressive disorder. The authors concluded that escitalopram was more effective and less costly than duloxetine. The methodology appears to have been appropriate and, on the whole, was clearly and transparently reported. The conclusions

2008 NHS Economic Evaluation Database.

50. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

51. An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence

An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence Das Gupta R, Caiado M, Bamber L Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared five different options for the treatment of moderate-to-severe stress urinary incontinence (SUI). The options compared were: current standard treatment in the authors' setting; duloxetine alone as first-line treatment; duloxetine

2006 NHS Economic Evaluation Database.

52. Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training

Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

53. Duloxetine for fibromyalgia - horizon scanning review

Duloxetine for fibromyalgia - horizon scanning review Duloxetine for fibromyalgia - horizon scanning review Duloxetine for fibromyalgia - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Duloxetine for fibromyalgia - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 (...) Authors' objectives This study aims to summarise the currently available evidence on Duloxetine for fibromyalgia Authors' conclusions Duloxetine (Yentreve, Cymbalta, LY 248686) is a dual serotonin and noradrenaline re-uptake inhibitor (SNRI) in phase III trials for the management of the symptoms of fibromyalgia. If successful in licensing it will be the first pharmaceutical licensed for fibromyalgia. Two 12 week randomised, placebo controlled trials in 207 patients and 354 women, found that duloxetine

2005 Health Technology Assessment (HTA) Database.

54. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

55. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

56. Cymbalta (Duloxetine Hydrochloride)

Cymbalta (Duloxetine Hydrochloride) Drug Approval Package: Cymbalta (Duloxetine Hydrochloride) NDA #021427 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Cymbalta (Duloxetine Hydrochloride) Capsules Company: Eli Lilly & Co., Inc. Application No.: 021427 Approval Date: 8/03/2004 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) Chemistry Review(s) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) Clinical Pharmacology Biopharmaceutics

2004 FDA - Drug Approval Package

57. Duloxetine for major depressive disorder and stress urinary incontinence

Duloxetine for major depressive disorder and stress urinary incontinence Duloxetine for major depressive disorder and stress urinary incontinence Duloxetine for major depressive disorder and stress urinary incontinence Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian (...) Coordinating Office for Health Technology Assessment. Duloxetine for major depressive disorder and stress urinary incontinence. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of duloxetine hydrochloride (Trade Mark: Cymbalta) for the treatment of major depressive disorder and stress urinary incontinence in women. Authors' conclusions Duloxetine is another choice in the growing list of marketed

2004 Health Technology Assessment (HTA) Database.